Diagnostic Advisory Board
The Company’s medical team is led by Professor Gordon Stamp, who is a pathologist with over 30 years of experience in diagnostic oncology and chronic inflammatory disorders.
Professor Gordon Stamp is a Consultant Pathologist specialising in histopathology and has over 30 years experience in a wide range of differing oncological and chronic inflammatory disorders. Prof Stamp is widely published and was co-author of the text book ‘Advanced Histopathology’. He worked as Scientific Head of Unit for the CRUK London Research Institute undertaking immunohistochemistry, in situ hybridisation and imaging of experimental models of cancer and other diseases as well as Translational Research projects.
Prof Stamp has a particular interest in digital pathology and has worked in several centres of excellence including Liverpool University, Imperial College School of Medicine and the Royal Marsden Hospital. He has extensive experience in using and developing techniques in immunohistochemistry and molecular biology. Prof Stamp works actively with professional colleagues particularly with multi-disciplinary team (MDT) meetings and is passionate about ensuring patients receive the highest quality of diagnostic service.
Saheer Gharbia is Head of Genomics Research at Public Health England and works at The Royal London Hospital Medical College. Prof Gharbia is the HSW Director of Service Development and Opportunities. She leads on the establishment and development of the genetic testing service for infection, cancer and rare diseases. She also leads on partnership development and collaboration for Horizon Scanning and the introduction and phasing of new evidence-based diagnostic technologies.
Prof Gharbia has extensive experience in setting up new diagnostic services, the professional accreditation of service, the evaluation and selection of new IVDD (in vitro Diagnostic Devices) and evaluating for CE markers devices and kits. With the rapidly expanding portfolio of new diagnostic testing methodologies and modalities (some of which tests are more effective and meaningful than others), this role is fundamental to the quality of on-going HSW service development and provision.
Professor Shah is a Consultant in Microbial Proteomics and development of Clinical Applications of Mass Spectrometry. As a Clinical Scientist working at Public Health England he headed a laboratory utilising Genomics, Proteomic and Mass Spectral techniques for the characterisation of microorganisms and for new biomarker discovery.
Professor Haroun N. Shah has been responsible for leading a major thrust into the development of separation and analytical techniques to study the architecture of bacterial cells, metabolism and mechanisms of pathogenicity in anaerobic bacteria that colonise the alimentary tract. He has held senior academic appointments at The University of London with intermittent periods in Canada and the Middle East. He took up post of Head of Molecular Identification Services, Health Protection Agency Centre (HPA) for Infections in 2013, London with a focus on the study of human pathogens.
His scientific success is driven by both integrating evidence-base solutions into operation and creating solid and robust teams that are flexible and innovative. His research experience bridges the range of inquisitive and exploratory research into biological mechanisms and markers of diversity to translating and implementing technology into biological solution. He is passionate about creating dynamic teams focussed on integrated solutions.
Through collaboration with Academic and Industrial Partners, he develops programmes of translating innovations in genomics and proteomics into tools for microbial analysis and prediction of pathogen behaviours. These collaborations allowed early access to biotechnologies and led to the development of platforms and software for advanced genomic analysis and re-sequencing approaches tailored to detect infectious agents and the award of several patents to the HPA/PHE in the area of diagnostics.
Throughout his career, he has maintained strong insight in industry innovations and has worked closely with leaders in biotechnology on the design, application and bringing on board new technologies and methodologies for clinical applications.